Abstract Number: 0583 • ACR Convergence 2021
Obesity and Lower Socioeconomic Position Are Independently Associated with Incident Osteoarthritis and Rheumatoid Arthritis: Results from the English Longitudinal Study of Ageing
Background/Purpose: Obesity is a known risk factor for OA and hypothesised as a risk factor for RA, although due to different underlying mechanisms. Lower socioeconomic…Abstract Number: 0613 • ACR Convergence 2021
Racial/Ethnic Disparities in Prescription Medications in a Large Urban Medical Center
Background/Purpose: African Americans and Hispanics with rheumatoid arthritis (RA) or systemic lupus erythematosus (SLE) continue to have worse disease-related health outcomes relative to Whites. This…Abstract Number: 0789 • ACR Convergence 2021
Adipokine Levels and Associations with Achievement of Low Disease Activity in Rheumatoid Arthritis
Background/Purpose: Adipokines are fat-secreted proteins that serve as metabolic regulators. Prior studies have identified associations between adipokines and disease characteristics such as disease activity and…Abstract Number: 0805 • ACR Convergence 2021
A Real-world Prospective Observational Study of the Effectiveness of Golimumab in Adult Greek Patients with RA, PsA and Axial SpA and Inadequate Response to Initial TNFα Inhibitor Therapy
Background/Purpose: Patients (pts) with immune-mediated rheumatic diseases and an insufficient response to previous treatment with TNFα inhibitors (TNFαi) are frequently encountered in clinical practice. This…Abstract Number: 0824 • ACR Convergence 2021
Physicians’ Reasons for Prescribing Janus Kinase Inhibitors (JAKi) in Patients with Rheumatoid Arthritis, and Associated Alignment Between Physicians and Patients in a Real-world Clinical Setting
Background/Purpose: Shared decision making, a cornerstone of rheumatoid arthritis (RA) management1, allows physicians and their patients to make informed decisions about their treatment goals and…Abstract Number: 0840 • ACR Convergence 2021
Modelling of Disease Activity in Patients with Inflammatory Arthropathies Treated with Etanercept Originator or Biosimilar as First-Line Biologic: A Real-World Observational Study Using the OPAL Dataset
Background/Purpose: The availability of biosimilars as non-proprietary versions of established biologic disease-modifying anti-rheumatic drugs (bDMARDs) has increased around the world. Since April 2017 both the…Abstract Number: 0990 • ACR Convergence 2021
Lower Incidence of COVID-19 but Higher Mortality in Patients with Inflammatory Arthritis Compared to Controls in Wales, United Kingdom: A Population Epidemiological Study
Background/Purpose: The COVID-19 pandemic has caused over 3 million deaths. Having inflammatory arthritis (IA) and anti-rheumatic medications increase the risk of infections. Comorbidities, common in…Abstract Number: 1073 • ACR Convergence 2021
In Favor of the Subspecialty Clinic Model for Rheumatoid Arthritis
Background/Purpose: The Subspecialty Clinic Model (SCM) which seeks to allow for collaborative care and services by stratifying patients with a particular disease or need to…Abstract Number: 1200 • ACR Convergence 2021
Predicting Progression to RA in Patients with Seropositive Arthralgia
Background/Purpose: Rheumatoid Arthritis (RA) is a chronic inflammatory condition often associated with joint destruction, disability, and reduced life expectancy. Before RA diagnosis, some patients may…Abstract Number: 1216 • ACR Convergence 2021
Evidence of a Tendency for Localized Recurrence of Arthritis in Rheumatoid Arthritis Patients
Background/Purpose: Local inflammation may cause synovial fibroblasts to become sensitized, resulting in higher susceptibility to arthritis. Longitudinal assessment of joint involvement in rheumatoid arthritis (RA)…Abstract Number: 1232 • ACR Convergence 2021
Synovial Tissue Lymphoid Aggregates Are Associated with Response to Rituximab Therapy in Rheumatoid Arthritis Patients
Background/Purpose: Activated B lymphocytes and plasma cells are implicated in the pathogenesis of rheumatoid arthritis (RA). The anti-CD20 monoclonal antibody therapy (Rituximab) is an effective…Abstract Number: 1248 • ACR Convergence 2021
Adjusted Analyses of the Benefits of Autoantibody Enrichment on Efficacy Outcomes in Early RA, from a Pooled Analysis of 4 Abatacept RCTs
Background/Purpose: Previous studies have found differential treatment efficacy of abatacept (ABA) for the treatment of RA based on biomarker-seropositivity.1-4 An earlier study found a differential…Abstract Number: 1445 • ACR Convergence 2021
Association Between Baseline Use of Rituximab and COVID-19 Outcomes in Patients with Rheumatoid Arthritis (RA)
Background/Purpose: Patients with Rheumatoid arthritis (RA) are at a potentially increased risk of SARS-CoV-2 infection, and immunosuppressive or biologic drugs used to treat RA might…Abstract Number: 1645 • ACR Convergence 2021
Elevations in Adipocytokines and Mortality in Rheumatoid Arthritis
Background/Purpose: Adipokines are metabolic regulators and are associated with adverse outcomes in chronic conditions and among older adults. Elevations in one adipokine, adiponectin, have been…Abstract Number: 1663 • ACR Convergence 2021
The Influence of Comorbidity on Mortality in Patients with Rheumatoid Arthritis 1980-2015: A Longitudinal Population-based Study in Western Australia
Background/Purpose: Rheumatoid arthritis (RA) contributes to excess morbidity and mortality in RA patients compared with the general population. In Australia, there is a paucity of…
- « Previous Page
- 1
- …
- 156
- 157
- 158
- 159
- 160
- …
- 219
- Next Page »
